RXST241220P85000
- 0.00
- 0.000.00%
RxSight Newsroom
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
RxSight Down Over 13%, on Pace for Largest Percent Decrease Since June 2022 -- Data Talk
Stifel Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $40
Hold Rating Issued Amidst Rising Competition and Market Uncertainty for RxSight
RxSight Cut to Hold at Stifel on Competition Concerns
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Do You Believe in the Long-Term Growth Potential of RxSight (RXST)?
Forecasting The Future: 4 Analyst Projections For RxSight
Positive Week for RxSight, Inc. (NASDAQ:RXST) Institutional Investors Who Lost 1.6% Over the Past Year
Stifel Downgrades RxSight to Hold, Lowers Price Target to $40
Institutional Owners May Consider Drastic Measures as RxSight, Inc.'s (NASDAQ:RXST) Recent US$258m Drop Adds to Long-term Losses
Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
RxSight Cut to Equal-Weight From Overweight by Wells Fargo
Wells Fargo Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $42
RxSight Analyst Ratings
UBS Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $52
RxSight's Promising Growth With Light Adjustable Lens: A Buy Recommendation by Danielle Antalffy
Insider Sale: Director at $RXST (RXST) Sells 3,782 Shares
3 'Buy' Stocks and 2 'Hold' Stocks According to Oppenheimer
RxSight (RXST) Upgraded to Buy: Here's What You Should Know